IL5 and infection: These overarching safety characteristics of anti-IL-5 medications, derived from signal detection, displayed general congruity with mepolizumab and benralizumab’s signal detection results, while the reslizumab results did not conspicuously depict events related to infections, product issues, and inappropriate usage (Appendices 7, 8 & 9).